Alto Neuroscience Inc.
ANRO | NYSE
$30.58
-$0.05 (-0.16%)
Sep 22, 2026, 2:21 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
Net Income | -63.24M | -61.43M | -36.31M | -27.71M | -9.19M |
Depreciation & Amortization | 661K | 502K | 373K | 342K | 145K |
Stock-Based Compensation | 8.11M | 7.63M | 2.89M | 1.76M | 227K |
Other Working Capital | -188K | 3.54M | -391K | 2.42M | 255K |
Other Non-Cash Items | 2.67M | 1.81M | 291K | 632K | 125K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 33K | 4.06M | -698K | 4.58M | -572K |
Operating Cash Flow | -51.77M | -47.42M | -33.45M | -20.39M | -9.26M |
Capital Expenditures | -24K | -2.08M | -470K | -732K | -680K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -24K | -2.08M | -470K | -732K | -680K |
Debt Repayment | 9.48M | 1.25M | n/a | 9.83M | n/a |
Common Stock Repurchased | -167K | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 67K | -3.14M | -2.05M | -341K | -205K |
Financial Cash Flow | 60.08M | 135.69M | 68.13M | 43.79M | 31.69M |
Net Cash Flow | 8.26M | 86.18M | 34.2M | 22.64M | 21.7M |
Free Cash Flow | -51.79M | -49.5M | -33.92M | -21.13M | -9.94M |
Adj. Free Cash Flow | -59.9M | -57.13M | -36.81M | -22.89M | -10.17M |
Maintenance CapEx | -24K | -2.08M | -470K | -732K | -680K |
Growth CapEx | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -51.79M | -49.5M | -33.92M | -21.13M | -9.94M |
Add to Watchlist
Select watchlists to add or remove ANRO